Biosimilars; opting for innovation

Biologics is Kern Pharma's division focused on biosimilar medicines.

Born from the merger of the company with Celltrion Healthcare, one of the leading biotech manufacturers in the world with its headquarters in Seoul (South Korea).

With this alliance, Kern Pharma makes Infliximab, Trastuzumab and Rituximab, three monoclonal antibodies approved by the EMA (Spanish Drug Agency) accessible to patients in Spain and Portugal.